Sixty Miles for a Prescription: The Market Failures and Policy Gaps Driving Rural Medication Inequity

For many Americans living in rural counties, a routine trip to the pharmacy is anything but routine. In parts of the Mississippi Delta, the Wyoming high plains, and the Appalachian interior, the nearest dispensing pharmacy may sit an hour's drive away—across roads that become impassable in winter, in communities where vehicle ownership is not guaranteed and public transportation is effectively nonexistent. What urban policymakers frequently characterize as a logistical inconvenience is, in these contexts, a genuine barrier to continuous medication adherence, and by extension, a driver of preventable hospitalization and premature mortality.

The phenomenon is increasingly described in the literature as the pharmacy desert—defined by the National Community Pharmacists Association as a census tract in which residents must travel more than ten miles to reach a retail pharmacy. By that measure, more than 41 million Americans reside in pharmacy deserts, the overwhelming majority of them in rural or exurban geographies. Yet the distance metric alone understates the problem. Rural patients who do reach a pharmacy frequently encounter a second inequity: they pay more.

The Consolidation Engine

The structural origins of pharmacy deserts are not mysterious. Over the past two decades, the American retail pharmacy sector has undergone dramatic consolidation. Three chains—CVS Health, Walgreens Boots Alliance, and Rite Aid—at one point controlled more than a third of all retail pharmacy locations in the United States. Simultaneously, independent community pharmacies, which have historically anchored medication access in small towns, have been closing at a rate of several hundred per year. Between 2003 and 2022, the number of independent pharmacies declined by approximately 18 percent, with rural closures disproportionately represented.

The mechanisms driving these closures are well-documented in the pharmacoeconomic literature. Pharmacy Benefit Managers (PBMs)—the intermediary companies that negotiate drug pricing between manufacturers, insurers, and dispensing pharmacies—have been widely criticized for reimbursement structures that systematically disadvantage independent and rural pharmacies. DIR fees (Direct and Indirect Remuneration fees), which PBMs may claw back from pharmacies months after a prescription is dispensed, have been identified in multiple studies as financially destabilizing for lower-volume rural operations that lack the bargaining leverage of large chains.

A 2021 report from the Government Accountability Office found that DIR fees increased by more than 107,000 percent between 2010 and 2019, with small pharmacies bearing a disproportionate burden. For a rural pharmacy dispensing several hundred prescriptions per week—rather than several thousand—these fees can render operations economically unviable, accelerating the very closures that produce desert conditions.

The Price Paradox

Perhaps the most counterintuitive dimension of the pharmacy desert problem is the pricing inversion it produces. Conventional economic logic might suggest that urban markets, with their greater competition, would offer consumers lower prices. In the pharmaceutical context, this intuition broadly holds for insured patients with access to large-chain negotiated formularies. However, for uninsured and underinsured rural patients—a population that skews older, lower-income, and more likely to be managing multiple chronic conditions—the pricing landscape is markedly different.

Without the competitive pressure of multiple nearby dispensaries, rural pharmacies operating as local monopolies have less incentive to discount cash prices. Furthermore, rural patients are less likely to be enrolled in employer-sponsored insurance plans that carry negotiated drug pricing, and more likely to depend on Medicare Part D plans with higher cost-sharing tiers. A 2023 analysis published in the Journal of Rural Health found that uninsured rural patients paid, on average, 23 percent more for a standard 30-day supply of common chronic disease medications—including metformin, lisinopril, and atorvastatin—than their urban counterparts at chain pharmacies.

The cumulative financial burden on rural households managing multiple chronic conditions can be substantial. For a retired farmer in rural Kentucky managing hypertension, type 2 diabetes, and hyperlipidemia, the combined premium of geographic inaccessibility and elevated cash pricing may force rationing decisions that directly compromise health outcomes.

Telehealth and Mail-Order: Partial Remedies with Structural Limitations

Policymakers and industry advocates have frequently pointed to mail-order pharmacy and telepharmacy services as solutions to the desert problem. Both modalities have expanded meaningfully in the post-pandemic period, and there is genuine evidence that mail-order programs can reduce out-of-pocket costs for patients on stable, long-term medication regimens. However, these solutions carry important limitations that constrain their applicability as universal remedies.

Mail-order pharmacy is poorly suited to acute prescriptions, controlled substances, and medications requiring patient counseling or cold-chain handling. Telepharmacy—in which a remote pharmacist supervises a technician at a rural dispensing site via videoconference—addresses some of these gaps but requires robust broadband infrastructure, which remains unevenly distributed across rural America. According to the Federal Communications Commission's 2022 Broadband Deployment Report, approximately 14.5 million rural Americans still lack access to fixed broadband at threshold speeds, undermining the premise of digital pharmacy access as an equitable substitute for physical presence.

A Federal Framework for Medication Access Equity

The evidence base collectively argues for a federal regulatory response that moves beyond voluntary market incentives. Several policy instruments merit serious consideration.

First, reform of PBM reimbursement structures—specifically the elimination or strict limitation of retroactive DIR fees—would directly address one of the primary financial pressures forcing rural pharmacy closures. The Centers for Medicare and Medicaid Services implemented partial DIR fee reform effective January 2024, capping retroactive adjustments for Medicare Part D dispensing. While this represents meaningful progress, the reform does not extend to commercial insurance markets, where independent rural pharmacies remain exposed.

Second, Congress could authorize the Health Resources and Services Administration (HRSA) to designate pharmacy deserts as a formal category of health professional shortage area, making affected communities eligible for targeted grant funding and loan forgiveness programs for pharmacists willing to practice in underserved rural geographies. Analogous programs for physicians and dentists have demonstrated measurable impact on provider distribution.

Third, states with significant rural populations should be encouraged—and where appropriate, federally incentivized—to expand telepharmacy licensing frameworks and invest in broadband infrastructure as a health infrastructure priority, not merely a commercial one.

Finally, and perhaps most ambitiously, a federal medication access equity standard—modeled loosely on the concept of universal service obligations in telecommunications—could establish minimum geographic access benchmarks that pharmacy benefit structures and state licensing regimes would be required to meet. Such a standard would represent a significant departure from the market-driven architecture that has historically governed pharmaceutical distribution in the United States, but the evidence suggests that market mechanisms alone have not produced, and are unlikely to produce, equitable outcomes.

Conclusion

The pharmacy desert is not an accident of geography. It is a predictable consequence of policy choices—about how pharmaceutical distribution is organized, how intermediaries are compensated, and how rural health infrastructure is prioritized relative to urban and suburban markets. The Americans bearing the costs of these choices are disproportionately elderly, low-income, and managing chronic conditions that demand consistent medication access. Addressing this inequity will require regulatory interventions that rebalance market incentives, protect independent rural pharmacies, and establish explicit federal standards for equitable medication access. The evidence to justify such interventions is substantial. What remains is the political will to act on it.